A detailed history of Golden State Equity Partners transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Golden State Equity Partners holds 260 shares of BEAM stock, worth $6,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares
260
Holding current value
$6,786
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$22.57 - $33.14 $5,868 - $8,616
260 New
260 $6,000
Q1 2023

Jun 01, 2023

SELL
$30.15 - $48.79 $292,153 - $472,775
-9,690 Closed
0 $0
Q1 2022

May 18, 2022

BUY
$53.73 - $82.16 $520,643 - $796,130
9,690 New
9,690 $555,000
Q1 2022

May 16, 2022

SELL
$53.73 - $82.16 $354,618 - $542,256
-6,600 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$68.02 - $99.06 $448,932 - $653,796
6,600 New
6,600 $526,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.84B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Golden State Equity Partners Portfolio

Follow Golden State Equity Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

News

Stay updated on Golden State Equity Partners with notifications on news.